[Surgical and percutaneous treatment of hypertrophic obstructive cardiomyopathy: state-of-the-art review] [0.03%]
肥厚型梗阻性心肌病的外科和经皮治疗：现状分析
Maria Sabrina Ferrante,Calogera Pisano,Giuseppe Maria Raffa et al.
Maria Sabrina Ferrante et al.
Hypertrophic cardiomyopathy is a heterogeneous and complex disease. It is an autosomal dominant genetic disease caused by a missense mutation in one of at least 12 genes that code for cardiac sarcomere proteins. There are various approaches...
[Kidney protection: role of sodium-glucose co-transporter 2 inhibitors and finerenone] [0.03%]
肾脏保护：钠葡萄糖共转运体2抑制剂和非奈利酮的作用
Manuela Benvenuto,Emilia D&#x;Elia,Marco Cittar et al.
Manuela Benvenuto et al.
Chronic kidney disease, diabetes mellitus and heart failure represent three chronic conditions closely linked to each other from a pathophysiological and prognostic point of view. This link has led to an ever-increasing emphasis in recent y...
Simona Giubilato,Leonardo De Luca
Simona Giubilato
Despite the effectiveness of statins in reducing cardiovascular events and slowing the progression of coronary atherosclerosis, significant residual cardiovascular risk persists. In the REDUCE-IT trial, icosapent ethyl (IPE), a highly purif...
[After the ISCHEMIA trial and the new guidelines, does it still make sense to search for myocardial ischemia? When should a patient with chronic coronary syndrome be revascularized?] [0.03%]
ISCHEMIA试验和新指南之后，慢性冠脉综合征患者的缺血筛查及血运重建指征发生了哪些变化？
Stefano Urbinati
Stefano Urbinati
The ISCHEMIA study enrolled patients with chronic coronary syndrome, moderate-to-severe myocardial ischemia, and critical coronary stenosis, demonstrating that coronary revascularization is not superior to optimized medical therapy in a pop...
[Artificial intelligence for randomized controlled trials in cardiology: applications and future perspectives] [0.03%]
[心血管病学随机对照试验的人工智能应用及未来展望]
Christian Basile,Alessandro Villaschi,Francesco Orso et al.
Christian Basile et al.
Integrating artificial intelligence (AI) into cardiovascular clinical trials is emerging as a key factor in streamlining patient selection, data collection, endpoint monitoring, and outcome analysis. On the one hand, machine learning and de...
Mattia Petrungaro,Mario Malavasi,Gianfranco Notarianni
Mattia Petrungaro
[2025 ACC/AHA guidelines for the management of acute coronary syndromes: what's new and comparison with the 2023 ESC guidelines] [0.03%]
2025 AHA/ACC急性冠脉综合征管理指南更新要点及与2023 ESC指南对比
Stefano Savonitto,Stefano De Servi
Stefano Savonitto
[Real-world experience with early use of vericiguat in worsening heart failure] [0.03%]
伏葛司曲格列汀治疗恶化的心力衰竭的早期应用经验
Laura Scelsi
Laura Scelsi
Background: Despite guideline-directed medical therapy for heart failure with reduced ejection fraction (HFrEF), a residual risk of adverse outcomes persists, particularly after worsening heart failure (WHF). The VICTORIA...